Skip to main content

Advertisement

SpringerLink
Log in

Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate visual outcomes in combination therapy with photodynamic therapy (PDT) and intravitreal triamcinolone acetonide (IVTA) for subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD).

Methods

Charts of 39 eyes from 38 patients with exudative AMD treated with PDT and 4 mg of triamcinolone acetate injected intravitreally were reviewed retrospectively. Visual data, angiographic lesion type, prior PDT exposure, number of treatments, and follow-up were recorded. Snellen visual acuities were converted to LogMAR for all calculations. Lines of vision lost or gained pertain to calculated ETDRS lines of vision (via LogMAR).

Results

Twenty-two of the choroidal neovascular membranes were occult, and 17 were classified as predominantly classic. Mean follow-up was 43 weeks. The average number of treatments was 2.23. At final follow-up, 11 eyes (28.21%) experienced improved visual acuity, 8 eyes (20.51%) were stable, and 20 eyes (51.28%) had worsened. No significant difference in treatment response was found between angiographic subtypes (p > 0.59). Lack of previous PDT exposure did not improve treatment outcomes (p > 0.77). Pre-treatment visual acuity (PTVA) was determined as a strong predictor of treatment outcome in our study cohort. Visual acuity of 20/200 or worse was associated with a 40.9% chance of some improvement and a 35.75% chance of three or more lines of improvement. Visual acuity better than 20/200 was associated with an 89.4% chance of no improvement and a 58.8% chance of three or more lines of visual loss.

Conclusion

Counter to previously reported results with combination therapy, the majority of our patients (72%) did not demonstrate improved vision and 51% lost vision. When PTVA was accounted for, selected patients benefitted significantly from treatment. PTVA may be a useful and simple patient selection tool for combination treatment with PDT and IVTA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Smith W, Assink J et al (2001) Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 108(4):697–704

    Article  PubMed  CAS  Google Scholar 

  2. Macular Photocoagulation Study Group (1991) Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 109:1242–1257

    Google Scholar 

  3. Pauleikhoff D, Bornfeld N et al (2005) Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenarzte-Stellungnahme zur aktuellen Therapie der neovaskularen AMD. Klinische Monatsblatter fur Augenheilkunde 222(5):381–388

    Article  PubMed  CAS  Google Scholar 

  4. Chakravarthy U, Soubrane G et al (2006) Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 90(9):1188–1196

    Article  PubMed  CAS  Google Scholar 

  5. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19(3):361–372

    PubMed  Google Scholar 

  6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444

    Article  PubMed  CAS  Google Scholar 

  7. Bressler NM (2001) Treatment of age-related macular degeneration with photodynamic therapy study. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119(2):198–207

    PubMed  CAS  Google Scholar 

  8. Verteporfin In Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131(5):541–560

    Article  Google Scholar 

  9. Bressler NM (2002) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 133(1):168–169

    Article  PubMed  Google Scholar 

  10. Bressler NM et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report no. 3. Arch Ophthalmol 120(11):1443–1454

    PubMed  CAS  Google Scholar 

  11. Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113(1):14–22

    Article  PubMed  Google Scholar 

  12. Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 141(4):638–645

    Article  PubMed  CAS  Google Scholar 

  13. Spaide RF, Sorenson J et al (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110(8):1517–1525

    Article  PubMed  Google Scholar 

  14. Spaide RF, Sorenson J et al (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112(2):301–304

    Article  PubMed  Google Scholar 

  15. Nicolo M, Ghiglione D et al (2006) Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 26(1):58–64

    Article  PubMed  Google Scholar 

  16. Spaide RF, Sorenson J et al (2005) Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 25(6):685–690

    Article  PubMed  Google Scholar 

  17. Chan WM, Lai TY et al (2006) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 90(3):337–341

    Article  PubMed  Google Scholar 

  18. Ergun E, Maar N et al (2006) Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 142(1):10–16

    Article  PubMed  CAS  Google Scholar 

  19. Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391

    PubMed  CAS  Google Scholar 

  20. Blyth CR, Still HA (1983) Binomial confidence intervals. J Am Stat Assoc 78:108–116

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, Barnes Retina Institute, 660 S. Euclid Avenue, Box 8096, St. Louis, MO, 63110, USA

    Ramin Schadlu, Steven M. Kymes & Rajendra S. Apte

Authors
  1. Ramin Schadlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven M. Kymes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rajendra S. Apte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajendra S. Apte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schadlu, R., Kymes, S.M. & Apte, R.S. Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response. Graefes Arch Clin Exp Ophthalmol 245, 1667–1672 (2007). https://doi.org/10.1007/s00417-007-0619-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-007-0619-0

Keywords

Search

Navigation